TOUS - ETF AI Analysis

Top Page

T. Rowe Price International Equity ETF (TOUS)

Rating:65Neutral

Price Target:―

The T. Rowe Price International Equity ETF (TOUS) demonstrates solid performance driven by strong holdings like AstraZeneca and ASML Holding NV. AstraZeneca contributes positively with robust revenue growth and a successful product pipeline, while ASML benefits from strong financials and potential undervaluation. However, weaker holdings like Rolls-Royce, which faces financial stability concerns, slightly temper the overall rating. A key risk factor is the ETF's exposure to stocks with high valuation concerns, which could impact future returns.

Positive Factors

Strong Top Holdings

Several key holdings, such as Rolls-Royce and UniCredit, have delivered strong year-to-date performance, driving the fund’s returns.

Global Diversification

The ETF invests across multiple countries, including Japan, the UK, and France, reducing reliance on any single market.

Balanced Sector Exposure

The fund is spread across various sectors like Financials, Industrials, and Technology, helping to mitigate sector-specific risks.

Negative Factors

Moderate Expense Ratio

The ETF’s expense ratio is higher than some low-cost alternatives, which could slightly reduce long-term returns.

Underperforming Holdings

Some top holdings, like SAP SE, have shown weak year-to-date performance, potentially dragging on overall returns.

Limited U.S. Exposure

With only 10% of assets in U.S. companies, the fund may miss out on opportunities in the world’s largest economy.

TOUS vs. SPDR S&P 500 ETF (SPY)

AUM1.08B

RegionDeveloped Markets

Expense Ratio0.50%

Beta0.70

IssuerT. Rowe Price

Inception DateJun 14, 2023

Dividend Yield2.28%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume121,150

30 Day Avg. Volume169,584

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

39.24

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering178

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

TOUS Summary

The T. Rowe Price International Equity ETF (TOUS) is an investment fund that gives you access to a wide range of companies from around the world, including both developed and emerging markets. It focuses on a 'Total Market' approach, meaning it includes companies of all sizes and styles. Some well-known companies in this ETF are ASML Holding NV and AstraZeneca. This ETF is a good option for investors looking to diversify their portfolio globally and benefit from international growth opportunities. However, since it invests in global markets, its performance can be affected by economic and political changes in different countries.

How much will it cost me?The T. Rowe Price International Equity ETF (TOUS) has an expense ratio of 0.5%, which means you’ll pay $5 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed, meaning professional managers are selecting investments rather than tracking a passive index.

What would affect this ETF?The T. Rowe Price International Equity ETF (TOUS) could benefit from growth in developed markets outside the U.S., particularly in sectors like financials, technology, and health care, which make up a significant portion of its holdings. However, potential risks include economic slowdowns in key regions, regulatory changes affecting top holdings like ASML or AstraZeneca, and currency fluctuations that could impact returns for U.S.-based investors. Global interest rate changes and geopolitical tensions may also influence the ETF's performance.

TOUS Top 10 Holdings

The T. Rowe Price International Equity ETF (TOUS) leans heavily on developed markets outside the U.S., with a notable focus on financials and industrials. Rolls-Royce is soaring this year, helping to lift the fund, though recent short-term weakness has tempered its momentum. AstraZeneca and Roche are steady performers, benefiting from strong pipelines in healthcare, while ASML Holding, a key player in technology, has shown mixed signals, with long-term gains but recent softness. Meanwhile, Unilever has struggled to gain traction, holding back some of the fund’s progress. Overall, the ETF offers a diverse but sector-tilted global mix.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
ASML	ASML Holding NV	2.84%	$30.82M	€353.45B	34.96%	76 Outperform
AZN	AstraZeneca	2.53%	$27.44M	$278.70B	34.92%	79 Outperform
RR	Rolls-Royce Holdings	1.96%	$21.21M	£92.13B	102.63%	71 Outperform
UCG	UniCredit SpA	1.86%	$20.15M	€105.11B	96.10%	75 Outperform
ROG	Roche Holding AG	1.43%	$15.51M	CHF253.28B	42.40%	73 Outperform
SIE	Siemens	1.34%	$14.55M	€185.66B	22.73%	74 Outperform
ULVR	Unilever	1.31%	$14.25M	£105.45B	-7.82%	72 Outperform
6723	Renesas Electronics	1.30%	$14.10M	¥3.90T	2.44%	64 Neutral
8306	Mitsubishi UFJ Financial Group	1.29%	$14.04M	¥27.94T	39.00%	76 Outperform
CS	AXA SA	1.25%	$13.58M	€84.96B	18.30%	75 Outperform

TOUS Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

33.86

Positive

100DMA

33.48

Positive

200DMA

32.01

Positive

Market Momentum

MACD

0.22

Negative

RSI

59.10

Neutral

STOCH

85.64

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TOUS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 33.93, equal to the 50-day MA of 33.86, and equal to the 200-day MA of 32.01, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 59.10 is Neutral, neither overbought nor oversold. The STOCH value of 85.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TOUS.

TOUS Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
TOUS	―	―	$1.08B	0.50%	―
DFAI	―	―	$12.67B	0.18%	―
DIHP	―	―	$4.97B	0.28%	―
DFIS	―	―	$4.64B	0.39%	―
DISV	―	―	$3.98B	0.42%	―
CGIE	―	―	$1.33B	0.54%	―

Performance Comparison

TOUS

T. Rowe Price International Equity ETF

34.53

7.70

28.70%

DFAI

Dimensional International Core Equity Market ETF

―

DIHP

Dimensional International High Profitability ETF

―

DFIS

Dimensional International Small Cap ETF

―

DISV

Dimensional International Small Cap Value ETF

―

CGIE

Capital Group International Equity ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents